Psilocybin

Dumont Global Names New Partner, Shaunak Misra

Retrieved on: 
Monday, January 30, 2023
Partner, Value, Psilocybin, Knowledge, Dean, Partnership, Columbia University, Growth, Therapy, Cannabis, Research, Dumont, Delhi University, MBA, Financial services, Misra

New York, New York--(Newsfile Corp. - January 30, 2023) - Generalist long/short hedge fund, Dumont Global has just announced that it has named a new partner, Shaunak Misra.

Key Points: 
  • New York, New York--(Newsfile Corp. - January 30, 2023) - Generalist long/short hedge fund, Dumont Global has just announced that it has named a new partner, Shaunak Misra.
  • As a Partner and Senior Analyst at Dumont, Misra will be leading research into Dumont's "orphaned asset" strategy.
  • Dumont Global was founded as a private investment partnership in 2018 by Chris Yetter and the partners of 3G Capital.
  • Dumont Global is a private investment partnership specializing in orphaned assets, hedge funds, and cannabis.

Kaya Enters Jamaica’s Legal Psilocybin Market

Retrieved on: 
Wednesday, January 11, 2023
Psilocybin, Major depressive disorder, Attention, University, OTC, Depression, Anxiety, Government, Safety, LOS, FDA, University of California, Johns Hopkins University, Marketing, Food, Capsule, Post-traumatic stress disorder, Research, Food and Drug Administration, Pharmaceutical industry, Tourism, New York University

KINGSTON, Jamaica and LOS ANGELES, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Kaya Group ("Kaya" or "the Company") (OTC: NUGL), the first medicinal Ganja herb house in the Caribbean and holistic, wellness-focused ecosystem, announced today its Kaya Extracts subsidiary plans to enter the legal psilocybin market in Jamaica where the laws are relaxed, targeting the multibillion-dollar industry for the development, marketing and distribution of psilocybin mushrooms.

Key Points: 
  • KINGSTON, Jamaica and LOS ANGELES, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Kaya Group ("Kaya" or "the Company") (OTC: NUGL), the first medicinal Ganja herb house in the Caribbean and holistic, wellness-focused ecosystem, announced today its Kaya Extracts subsidiary plans to enter the legal psilocybin market in Jamaica where the laws are relaxed, targeting the multibillion-dollar industry for the development, marketing and distribution of psilocybin mushrooms.
  • This will include Kaya's current rollout of traditional Jamaica Psilocybin Mushroom and Capsules at its Herbhouse locations in Falmouth, Ocho Rios, and Kingston.
  • The first milestone includes developing and launching our nutraceuticals' range of psilocybin concentrations from micro-doses to hallucinogenic levels of dosing.
  • As a leader in the plant-based wellness industry, Kaya is committed to providing high-quality, responsibly sourced psilocybin products.

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Retrieved on: 
Tuesday, January 10, 2023
Psilocybin, University of California, San Francisco, Parkinson's disease, University, Data collection, Trial of the century, CTSI, Chronic pain, Therapy, Patient, Research, Clinical, Clinical trial, Bipolar disorder, Human, Peptide, SILO, UCSF, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Jan. 10, 2023 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its sponsored research study with the University of California, San Francisco (UCSF) examining psilocybin’s effect on inflammatory activity in humans. The clinical study evaluates three populations of patients suffering from Parkinson's disease, bipolar disorder, and chronic pain.

Key Points: 
  • The clinical study evaluates three populations of patients suffering from Parkinson's disease, bipolar disorder, and chronic pain.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, commented, “The UCSF research team is making progress on the clinical trial.
  • Utilizing Psilocybin in this study in a regimented dosing pattern, we hope to gain significant data both in mechanism of action and potential biomarker for personalization of psilocybin therapy.
  • Data collection is expected to begin in early 2023 for the bipolar study, and in April 2023 for the chronic pain study patients.

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Retrieved on: 
Monday, January 9, 2023
Psilocybin, IND, Psychopharmacology, Data, ACS, Emmanuel Berl, Depression, Mental health, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Safety, Reunion, TSX, FDA, SRC, The New England Journal of Medicine, Food, Patient, Drug discovery, Data analysis, Pharmaceutical industry

RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.

Key Points: 
  • RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.
  • In this first-in-human, Phase 1 study, RE104 was shown to be safe and well tolerated, with no serious or severe adverse events.
  • The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving placebo.
  • While completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee (SRC), Reunion has continued with dose escalation and initiated a fifth cohort.

Supermind Bolsters Marketing and Content Capabilities with Key Hires

Retrieved on: 
Wednesday, December 28, 2022
Psilocybin, Editorial, Education, Marketing, Mental health, Social media, PTSD, Optometry, American Addiction Centers, AMC, Executive, AMC Theatres, Inside Edition, BBC, Microsoft Band, Knowledge, NASA, Managing editor, Denver Broncos, Depression, Organization, FOX, IGN, THR, NBC, NPR, SEO, Acquisition, Ketamine, Emmy Awards, United States Air Force, NBCUniversal, Denver, Magic, Universal, Coca-Cola, APS, Fandom, Cooking, Content, Publishing, Senior, AMEX, Delta Air Lines, Management, Supermind, Sweetwater, ProMax

Dover, Delaware--(Newsfile Corp. - December 28, 2022) - Supermind announces the addition of new key talent for senior leadership positions, including Executive Vice President, Vice President of Content, Creative Director, Senior Editor, and Senior SEO Manager, rapidly growing its content and technical expertise. The team collectively brings 35 years of leadership, creative, technical, and marketing knowledge to bear, escalating Supermind's audience growth capabilities.

Key Points: 
  • The team collectively brings 35 years of leadership, creative, technical, and marketing knowledge to bear, escalating Supermind's audience growth capabilities.
  • The team collectively brings 35 years of leadership, creative, technical, and marketing knowledge to bear, escalating Supermind's audience growth capabilities.
  • Kevin helped to ensure that Recovery Brands maintained its dedication to ethical digital marketing within the addiction treatment space.
  • Vice President of Content, Roth Cornet, is a creative leader, strategic planner, and executive with 16 years of experience in production, publishing, and digital marketing.

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Retrieved on: 
Thursday, January 5, 2023
Death, Liver disease, Associate, MEAI, Morgan Stanley, Metabolism, Human, Research, Hebrew language, Triglyceride, Overweight, FSE, LSD, Risk, Stanley, Animal, Drug development, CSE, Fatty liver disease, World Health Organization, Psilocybin, Novo Nordisk, CWY, Weight loss, Metabolic syndrome, Therapy, Hebrew University of Jerusalem, Obesity, Eleazar Sukenik, Motivation, Lilly, Liver, Dietary supplement, Pharmaceutical industry, Yissum Research Development Company of the Hebrew University, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.

Key Points: 
  • It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
  • Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver.
  • Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
  • This underserved multibillion-dollar market creates significant opportunities for Clearmind to generate substantial revenues, should MEAI reach the market as an obesity treatment.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Reunion Neuroscience Inc. Provides 2023 Corporate Update

Retrieved on: 
Wednesday, January 4, 2023
Psilocybin, Tolerability, Selective serotonin reuptake inhibitor, Anxiety, ACS, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drug discovery, Hope, TSX, Depression, Mother, Interim analysis, Reunion, Patient, Pharmacodynamics, FDA, PPD, IND, Woman, Pharmaceutical industry, Safety

TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a corporate update for 2023 as it continues to advance its lead asset, RE104, through clinical development. As a proprietary, novel serotonergic psychedelic compound designed uniquely as a 4-OH-DiPT prodrug, RE104 is in development as a potential fast-acting, durable treatment for patients suffering from postpartum depression (PPD) and other mental health conditions.

Key Points: 
  • Reunion plans to report a preplanned interim analysis on 32 subjects from its first-in-human Phase 1 trial for RE104 in Q1 2023.
  • (2) What is the onset and duration of the psychoactive experience and pharmacokinetic profile of RE104 over a range of dose levels?
  • The Company plans to share detailed results from its Phase 1 study at a major medical meeting in the first half of 2023.
  • Once the PPD Phase 2 program is in progress, Reunion plans to share its continued RE104 development strategy in pursuit of treating additional indications.

Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023

Retrieved on: 
Wednesday, December 21, 2022
CBO, Interest, Therapy, CSE, Psilocybin, Conference, Pharmaceutical industry

KELOWNA, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that the Company will be presenting at the Biotech Showcase on Monday, January 9, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.

Key Points: 
  • KELOWNA, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that the Company will be presenting at the Biotech Showcase on Monday, January 9, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.
  • Biotech Showcase is an investor conference featuring insights from top investors and biopharma executives.
  • Interested parties can register to attend the event here:
    Additionally, CEO Jim Gilligan and CBO Peter Molloy will be in San Francisco from January 8-11, 2023, during the 41st Annual J.P. Morgan Health Care Conference and will be available for meetings with investors.